School of Medicine
Showing 1-10 of 11 Results
Steven Sanislo, MD
Clinical Professor, Ophthalmology
BioDr Sanislo has over 20 years of experience in clinical and surgical practice in retinal and vitreoretinal diseases. He is the senior vitreoretinal surgeon at Stanford and maintains a large clinical practice as well as teaching ophthalmology residents and retina fellows. He also participates in clincal reasearch for varying retinal conditions. Dr. Sanislo recieved ophthalmology training as a resident here at Stanford, and recieved vitreoretinal training as a fellow at the Cleveland Clinic Foundation.
Research interests include treatment of age-related macular degeneration, diabetic retinopathy and other retinal diseases.
Dr. Sanislo has extensive clinical and surgical experience in the following diseases:
- Age-related macular degeneration
- Posterior uveitis / infectious and inflammatory disease of the posterior segment
- Diabetic retinopathy
- Myopic degeneration / pathologic myopia
- Macular pucker / epiretinal membranes
- Macular hole
- Repair of simple and complex retinal detachments
- Macular edema
- Retinal vascular occlusion
Ann Shue, MD
Clinical Assistant Professor, Ophthalmology
Bio**Dr. Shue is taking new patients for glaucoma, cataracts, and adult strabismus.**
Ann Shue, MD, is a Clinical Assistant Professor of Ophthalmology at Stanford University School of Medicine, where she specializes in glaucoma, pediatric ophthalmology, and adult strabismus, a unique combination of subspecializations practiced by few surgeons worldwide. She is a board-certified ophthalmologist who completed fellowships in glaucoma at Yale University and pediatric ophthalmology and adult strabismus at Duke University. She practices at the Stanford Byers Eye Institute and the Lucile Packard Children's Hospital.
Dr. Shue loves seeing patients of all ages with eye problems big or small, including glaucoma due to any reason, glaucoma suspicion, family history of glaucoma, cataracts, strabismus (eye misalignment) or double vision from any cause, including after eye surgeries. She completed her ophthalmology residency at the University of Pittsburgh and an internal medicine internship at UCSF Fresno. She holds a medical degree from University of California, Irvine and an undergraduate degree in biology from Yale University.
Dr. Shue is a member of the American Glaucoma Society, the American Association for Pediatric Ophthalmology and Strabismus, and the UK Paediatric Glaucoma Society. She is active in presenting at regional and national conferences. She is the author of several journal articles and recently wrote two textbook chapters on pediatric glaucoma and pediatric glaucoma surgery.
Kuldev Singh, MD, MPH
Professor of Ophthalmology
Current Research and Scholarly InterestsGlaucoma, clinical epidemiology
Stephen Smith, MD
Clinical Assistant Professor, Ophthalmology
Current Research and Scholarly InterestsRESEARCH OVERVIEW
Dr. Smith’s primary professional interest is developing solutions for unmet clinical and surgical vitreoretinal needs. Beginning in medical school, one of his primary focuses has been improving treatment outcomes in patients with retinoblastoma (RB). During his second year in medical school Dr. Smith published a manuscript on a novel technique to reduce the risk of tumor spread following intravitreal drug delivery in patients with RB. His work summarizing published data on tumor spread following intravitreal injection therapy (IVT) for RB has resulted in multiple platform presentations at national and international meetings, including an invited lecture at ARVO 2014. The results of this study influenced the growing trend toward broader acceptance of intravitreal chemotherapy in pediatric patients with treatment-resistant retinoblastoma vitreous seeds. A primary active area of research has included studying and publishing on ocular toxicity that results from the use of intravitreal melphalan and other agents for RB. This work, and subsequent publications from leaders in the field, has led to an increased awareness of ocular toxicity caused by injecting chemotherapeutic agents into the eyes of young children. This highlighted the need for toxicity data on additional chemotherapeutic agents for local delivery. To answer this question, Dr. Smith assembled an excellent group of collaborators and consultants, including internationally known experts at Bascom Palmer, Mayo Clinic, and Emory University. As a resident he secured a highly competitive career starter grant from the Knights Templar Foundation and used that funding and the expertise of his collaborators to carry out preclinical ocular toxicity studies of combination intravitreal chemotherapy for RB. His work in RB has led to a broader recognition of the challenges facing patients with RB who receive IVT and has led to a continued search for optimal local injectable therapies for patients with this disease.
In addition to his work in retinoblastoma, Dr. Smith has been actively involved in developing technologies to improve outcomes for patients receiving intravitreal injection therapy (IVT) for macular degeneration, diabetic retinopathy, retinal vein occlusions and more. IVT has become the most common procedure performed by retina specialists in the United States, with an estimated 6 million injections given in the United States alone in 2016. Dr. Smith has co-developed technology that simplifies and streamlines the IVT process, removing barriers to treatment and improving patient outcomes. His work in innovation covers pre-clinical and clinical development work, and has given him expertise in diverse subject areas including fundraising, intellectual property portfolio development, team building, and business administration. He is a co-founder of iRenix Medical, a biotechnology and medical device start-up company committed to improving vision through optimization of the IVT process.
Dr. Smith remains dedicated to helping improve and restore vision and quality of life in patients with vitreoretinal disease. He is currently involved in both medical device and pharmaceutical innovation, and serves as a mentor for the Stanford University Biodesign Innovation Course.
Associate Professor of Anesthesiology, Perioperative and Pain Medicine (Adult MSD) and, by courtesy, of Ophthalmology
Current Research and Scholarly InterestsMechanisms promoting neuronal survival following cerebral ischemia-reperfusion injury; utilizing microRNA's to target multiple pathways to promote mitochondrial homeostasis and cell survival; anesthetic neurotoxicity; astrocyte-neuronal interaction
Yang Sun, MD, PhD
Associate Professor of Ophthalmology
Current Research and Scholarly InterestsWe are interested in the role of inositol phosphatases in eye development and disease, using both animal models and human disease tissue. We are a translational laboratory seeking to understand the basic function of proteins as well as developing therapeutic strategies for clinical trials.